Latest Health News

CONNEQT Health has raised $2 million through a convertible note facility with a director-owned entity, providing fresh capital to support its growth plans. Shareholder approval will be key to unlocking the full benefits of this funding.

Anatara Lifesciences has raised $1.2 million through a discounted share placement to fund its Anti-Obesity project and explore new opportunities. The capital injection reflects strong institutional support amid ongoing pipeline development.

OMG Group Limited has reported a remarkable 114% year-on-year increase in net sales for Q1 FY26, driven by robust ecommerce growth and expanding retail partnerships.

EVE Health Group has reached a pivotal milestone with the first patient prescriptions of Dyspro™, its cannabinoid-based treatment for dysmenorrhoea and endometriosis, alongside launching an educational platform to support patients and clinicians.

Biome Australia Limited has reported a record-breaking $5.94 million in sales revenue for Q1 FY26, surpassing forecasts and accelerating toward its ambitious Vision 27 revenue goals.

Wellnex Life Limited reported a robust 40.5% revenue increase in FY25, driven by the full-year integration of Pain Away, while margin recovery gains momentum in the second half.

Delorean Corporation has released its audited 2025 Annual Report, revealing key adjustments from its preliminary results including lower revenue, increased tax expenses, and a significant reclassification of borrowings.

FirstWave Cloud Technology has locked in a $2.5 million loan facility to accelerate its AI growth strategy and repay existing debt, complementing a recent $2.85 million equity raise.

Linius Technologies has released its audited FY2025 financial statements, revealing non-cash accounting adjustments related to Convertible Notes that increased reported losses and liabilities compared to prior unaudited figures.

Hydrix Limited delays its FY25 financial statements due to a pending independent valuation of its Wavewise Analytics shareholding, triggering an automatic trading suspension from 1 October 2025.

Orthocell has appointed its first Canadian distributor for Remplir, its innovative nerve repair device, ahead of an official launch at a major surgical conference in Vancouver. The move marks a significant step in expanding the product’s international footprint.

Dimerix Limited’s lead drug candidate DMX-200 has been granted Orphan Drug Designation in Japan for treating Focal Segmental Glomerulosclerosis (FSGS), enhancing its regulatory and commercial prospects in a key market.